Please Wait.....
Report
Middle East and Africa Stroke Market
Market Report I 2025-04-01 I 350 Pages I Data Bridge Market Research
The Middle East and Africa stroke market is expected to reach USD 1.71 billion by 2032 from USD 1.13 billion in 2024, growing at a substantial CAGR of 5.6% in the forecast period of 2025 to 2032.
Market Segmentation:
Middle East and Africa Stroke Market, By Type (Ischemic Stroke, Hemorrhage Stroke, and Transient Ischemic Attack (TIA)), Diagnosis & Treatment (Treatment and Diagnosis), Gender (Female and Male), End User (Hospitals & Clinics, Specialty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories, and Others), Distribution Channel (Direct, Retail, and Online), Country (South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Israel, and rest of Middle East and Africa) - Industry Trends & Forecast To 2032
Overview of the Middle East and Africa Stroke Market Dynamics:
Drivers
- Rising incidences of stroke drive demand for treatments
- Increasing number of patients with hypertension and coronary heart diseases
Restraints
- High cost of diagnosis
- Increase in product recalls
Opportunities
- High cost of diagnosis
- Increase in product recalls
Market Players:
The key market players for Middle East and Africa stroke market are listed below:
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd
- Sanofi
- Johnson & Johnson Services, Inc.
- Bayer AG
- Sandoz AG
- Pfizer Inc.
- Medtronic
- Abbott
- Viatris Inc.
- AstraZeneca
- Penumbra, Inc.
- GLENMARK PHARMACEUTICALS LTD
- Fresenius SE & Co. KGaA
- Teva Pharmaceuticals USA, Inc.
- Lupin
TABLE OF CONTENTS
1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 35
1.3 LIMITATIONS 37
1.4 MARKETS COVERED 37
2 MARKET SEGMENTATION 42
2.1 MARKETS COVERED 42
2.2 GEOGRAPHICAL SCOPE 43
2.3 YEARS CONSIDERED FOR THE STUDY 44
2.4 CURRENCY AND PRICING 44
2.5 DBMR TRIPOD DATA VALIDATION MODEL 45
2.6 MULTIVARIATE MODELLING 48
2.7 TYPE LIFELINE CURVE 48
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 49
2.9 DBMR MARKET POSITION GRID 50
2.10 MARKET END USER COVERAGE GRID 51
2.11 VENDOR SHARE ANALYSIS 52
2.12 SECONDARY SOURCES 53
2.13 ASSUMPTIONS 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 56
4.1 PESTEL ANALYSIS 59
4.2 PORTER'S FIVE FORCES 60
5 EUROPE STROKE MARKET, REGULATORY FRAMEWORK 61
5.1 REGULATION IN U.S. 61
5.2 REGULATION IN EUROPE 62
5.3 REGULATION IN CHINA 63
5.4 REGULATION IN JAPAN 63
5.5 REGULATION IN SOUTH AFRICA 64
6 MARKET OVERVIEW 65
6.1 DRIVERS 67
6.1.1 RISING INCIDENCES OF STROKE DRIVE DEMAND FOR TREATMENTS 67
6.1.2 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASES 68
6.1.3 INCREASING DIABETIC AND OBESE POPULATIONS ELEVATE STROKE RISKS 69
6.1.4 ADVANCEMENTS IN MEDICAL TECHNOLOGY IMPROVE STROKE CARE OUTCO.MES 69
6.2 RESTRAINTS 71
6.2.1 HIGH COST OF DIAGNOSIS 71
6.2.2 INCREASE IN PRODUCT RECALL 71
6.3 OPPORTUNITIES 73
6.3.1 DEVELOPMENT OF ADVANCED THERAPEUTICS FOR STROKES 73
6.3.2 EXPANSION IN STROKE REHABILITATION SERVICES 73
6.3.3 INNOVATIVE TREATMENTS IN PIPELINE FOR STROKE TREATMENT 74
6.4 CHALLENGES 75
6.4.1 FALSE DIAGNOSIS IN STROKES 75
6.4.2 COMPLICATIONS ASSOCIATED WITH MANAGING STROKE 76
7 EUROPE STROKE MARKET, BY TYPE 77
7.1 OVERVIEW 78
7.2 ISCHEMIC STROKE 81
7.2.1 THROMBOTIC (CEREBRAL THROMBOSIS) 82
7.2.2 EMBOLIC (CEREBRAL EMBOLISM) 82
7.3 HEMORRHAGIC STROKE 83
7.3.1 SUBARACHNOID HEMORRHAGE 83
7.3.2 INTRACEREBRAL HEMORRHAGE 83
7.4 TRANSIENT ISCHEMIC ATTACT (TIA) 84
8 EUROPE STROKE MARKET, BY GENDER 85
8.1 OVERVIEW 86
8.2 FEMALE 89
8.3 MALE 90
9 EUROPE STROKE MARKET, BY DIAGNOSIS AND TREATMENT 91
9.1 OVERVIEW 92
9.2 TREATMENT 95
9.2.1 BY TREATMENT TYPE 96
9.2.1.1 MEDICATION 96
9.2.1.1.1 MEDICATION, BY CLASS 96
9.2.1.1.1.1 BLOOD PRESSURE MEDICINES 97
9.2.1.1.1.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 98
9.2.1.1.1.1.2 RAMIPRIL 98
9.2.1.1.1.1.3 LISINOPRIL 98
9.2.1.1.1.1.4 ENALAPRIL 98
9.2.1.1.1.1.5 PERINDOPRIL 98
9.2.1.1.1.1.6 OTHER 98
9.2.1.1.1.2 THIAZIDE DIURETICS 99
9.2.1.1.1.2.1 INDAPAMIDE 99
9.2.1.1.1.2.2 BENDROFLUMETHIAZIDE 99
9.2.1.1.1.2.3 SPIRONOLACTONE 99
9.2.1.1.1.2.4 AMILORIDE 99
9.2.1.1.1.2.5 OTHER 99
9.2.1.1.1.3 CALCIUM CHANNEL BLOCKERS 100
9.2.1.1.1.3.1 AMLODIPINE 100
9.2.1.1.1.3.2 NIFEDIPINE 100
9.2.1.1.1.3.3 VERAPAMIL 100
9.2.1.1.1.3.4 NICARDIPINE 100
9.2.1.1.1.3.5 FELODIPINE 100
9.2.1.1.1.3.6 NIMODIPINE 100
9.2.1.1.1.3.7 OTHERS 100
9.2.1.1.1.4 BETA BLOCKERS 101
9.2.1.1.1.4.1 ATENOLOL 101
9.2.1.1.1.4.2 BISOPROLOL 101
9.2.1.1.1.4.3 LABETOLOL 101
9.2.1.1.1.4.4 OTHERS 101
9.2.1.1.1.5 ALPHA-BLOCKERS 102
9.2.1.1.1.5.1 DOXAZOSIN 102
9.2.1.1.1.5.2 OTHERS 102
9.2.1.1.1.6 OTHERS 102
9.2.1.1.1.7 ANTIPLATELET DRUGS 103
9.2.1.1.1.7.1 ASPIRIN 103
9.2.1.1.1.7.2 CLOPIDOGREL 103
9.2.1.1.1.7.3 DIPYRIDAMOLE 103
9.2.1.1.1.7.4 TICLOPIDINE 103
9.2.1.1.1.7.5 OTHERS 103
9.2.1.1.1.8 ANTICOAGULANTS 104
9.2.1.1.1.8.1 WARFARIN 104
9.2.1.1.1.8.2 APIXABAN 104
9.2.1.1.1.8.3 DABIGATRAN 104
9.2.1.1.1.8.4 HEPARIN 104
9.2.1.1.1.8.5 RIVAROXABAN 104
9.2.1.1.1.8.6 OTHERS 104
9.2.1.1.1.9 TISSUE PLASMINOGEN ACTIVATOR (TPA) 105
9.2.1.1.1.9.1 ALTEPLASE 105
9.2.1.1.1.9.2 TENECTEPLASE 105
9.2.1.1.1.9.3 RETEPLASE 105
9.2.1.1.1.9.4 ANISTREPLASE 105
9.2.1.1.1.9.5 OTHERS 105
9.2.1.1.1.10 STATINS 106
9.2.1.1.1.10.1.1 ATORVASTATIN 107
9.2.1.1.1.10.1.2 SIMVASTATIN 107
9.2.1.1.1.10.1.3 LOVASTATIN 107
9.2.1.1.1.10.1.4 ROSUVASTATIN 107
9.2.1.1.1.10.1.5 FLUVASTATIN 107
9.2.1.1.1.10.1.6 PRAVASTATIN 107
9.2.1.1.1.10.1.7 PITAVASTATIN 107
9.2.1.1.1.10.1.8 OTHERS 107
9.2.1.1.1.11 VITAMIN K 108
9.2.1.1.1.12 SUPPORTIVE MEDICATION 108
9.2.1.1.1.12.1 NUTRITIONAL SUPPLEMENTS 108
9.2.1.1.1.12.2 ANTIPYRETICS 108
9.2.1.1.1.12.3 OTHERS 108
9.2.1.1.2 MEDICATION, BY DRUG TYPE 109
9.2.1.1.2.1 BRANDED 109
9.2.1.1.2.1.1 ACTIVASE 110
9.2.1.1.2.1.2 EDOBAXAN 110
9.2.1.1.2.1.3 COUMADIN 110
9.2.1.1.2.1.4 HEPARIN LEO 110
9.2.1.1.2.1.5 DUOPLAVIN 110
9.2.1.1.2.1.6 AGGRENOX 110
9.2.1.1.2.1.7 RETAVASE 110
9.2.1.1.2.1.8 JANTOVEN 110
9.2.1.1.2.1.9 CATHFLO 110
9.2.1.1.2.1.10 OTHER 110
9.2.1.1.2.2 GENERIC 110
9.2.1.1.3 MEDICATION, BY ROUTE OF ADMINISTRATION 111
9.2.1.1.3.1 ORAL 111
9.2.1.1.3.1.1 TABLET 111
9.2.1.1.3.1.2 CAPSULES 111
9.2.1.1.3.1.3 OTHERS 111
9.2.1.1.3.2 PARENTERAL 112
9.2.1.1.3.2.1 INTRAVENOUS 112
9.2.1.1.3.2.2 SUBCUTANEOUS 112
9.2.1.1.3.3 OTHERS 112
9.2.1.1.4 MEDICATION, BY MODE OF PURCHASE 113
9.2.1.1.4.1 PRESCRIPTION 113
9.2.1.1.4.2 OVER THE COUNTER (OTC) 113
9.2.1.1.5 MEDICATION, BY THERAPY TYPE 113
9.2.1.1.5.1 COMBINATION THERAPY 113
9.2.1.1.5.2 MONOTHERAPY 113
9.2.1.2 SURGERY 114
9.2.1.2.1 EMBOLIC COILS 114
9.2.1.2.2 ASPIRATION CATHETERS 114
9.2.1.2.3 STENT RETRIEVER 114
9.2.1.2.4 SURGICAL CLIPPING 114
9.2.1.2.5 OTHERS 114
9.2.1.3 OTHERS THERAPY 115
9.2.1.3.1 PHYSICAL THERAPY 115
9.2.1.3.2 OCCUPATIONAL THERAPY 115
9.2.1.3.3 SPEECH THERAPY 115
9.2.1.3.4 OTHERS 115
9.3 DIAGNOSIS 116
9.3.1 IMAGING TEST 117
9.3.1.1 COMPUTERIZED TOMOGRAPHY (CT) SCAN 117
9.3.1.2 MAGNETIC RESONANCE IMAGING (MRI) 117
9.3.1.3 CAROTID ULTRASOUND 117
9.3.1.4 CEREBRAL ANGIOGRAM 117
9.3.2 BLOOD TEST 117
9.3.3 ECHOCARDIOGRAM 117
9.3.4 LUMBAR PUNCTURE 117
9.3.5 OTHERS 117
10 EUROPE STROKE MARKET, BY DISTRIBUTION CHANNEL 118
10.1 OVERVIEW 119
10.2 DIRECT 122
10.3 RETAIL 123
10.4 ONLINE 123
11 EUROPE STROKE MARKET, BY END USER 124
11.1 OVERVIEW 125
11.2 HOSPITALS & CLINICS 128
11.3 SPECIALTY CLINICS 129
11.4 AMBULATORY SURGICAL CENTER 129
11.5 HOMECARE 130
11.6 LABORATORIES 130
11.7 OTHERS 131
12 EUROPE STROKE MARKET, BY REGION 132
12.1 EUROPE 134
12.1.1 GERMANY 147
12.1.2 U.K. 158
12.1.3 FRANCE 169
12.1.4 ITALY 180
12.1.5 SPAIN 191
12.1.6 RUSSIA 202
12.1.7 NETHERLANDS 212
12.1.8 SWITZERLAND 223
12.1.9 TURKEY 233
12.1.10 AUSTRIA 243
12.1.11 POLAND 254
12.1.12 NORWAY 264
12.1.13 IRELAND 274
12.1.14 REST OF EUROPE 284
13 EUROPE STROKE MARKET, COMPANY LANDSCAPE 285
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT ANALYSIS 286
15 COMPANY PROFILES 287
15.1 BRISTOL-MYERS SQUIBB COMPANY 287
15.1.1 COMPANY SNAPSHOT 287
15.1.2 REVENUE ANALYSIS 288
15.1.3 COMPANY SHARE ANALYSIS 288
15.1.4 PRODUCT PORTFOLIO 288
15.2 F. HOFFMANN-LA ROCHE LTD 290
15.2.1 COMPANY SNAPSHOT 290
15.2.2 REVENUE ANALYSIS 291
15.2.3 COMPANY SHARE ANALYSIS 291
15.2.4 PRODUCT PORTFOLIO 292
15.2.5 RECENT DEVELOPMENT 292
15.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 293
15.3.1 COMPANY SNAPSHOT 293
15.3.2 COMPANY SHARE ANALYSIS 293
15.3.3 PRODUCT PORTFOLIO 294
15.3.4 RECENT DEVELOPMENT 295
15.4 DAIICHI SANKYO COMPANY, LIMITED 296
15.4.1 COMPANY SNAPSHOT 296
15.4.2 REVENUE ANALYSIS 296
15.4.3 COMPANY SHARE ANALYSIS 297
15.4.4 PRODUCT PORTFOLIO 297
15.4.5 RECENT DEVELOPMENT 298
15.5 SANOFI 299
15.5.1 COMPANY SNAPSHOT 299
15.5.2 REVENUE ANALYSIS 299
15.5.3 COMPANY SHARE ANALYSIS 300
15.5.4 PRODUCT PORTFOLIO 300
15.6 ABBOTT 301
15.6.1 COMPANY SNAPSHOT 301
15.6.2 REVENUE ANALYSIS 301
15.6.3 PRODUCT PORTFOLIO 302
15.6.4 RECENT DEVELOPMENT 302
15.7 AMNEAL PHARMACEUTICALS LLC 304
15.7.1 COMPANY SNAPSHOT 304
15.7.2 REVENUE ANALYSIS 304
15.7.3 PRODUCT PORTFOLIO 305
15.7.4 RECENT DEVELOPMENT 305
15.8 ASTRAZENECA 306
15.8.1 COMPANY SNAPSHOT 306
15.8.2 REVENUE ANALYSIS 306
15.8.3 PRODUCT PORTFOLIO 307
15.8.4 RECENT DEVELOPMENT 307
15.9 BAYER AG 308
15.9.1 COMPANY SNAPSHOT 308
15.9.2 REVENUE ANALYSIS 309
15.9.3 PRODUCT PORTFOLIO 309
15.9.4 RECENT DEVELOPMENT 310
15.10 FRESENIUS SE & CO. KGAA 312
15.10.1 COMPANY SNAPSHOT 312
15.10.2 REVENUE ANALYSIS 312
15.10.3 PRODUCT PORTFOLIO 313
15.10.4 RECENT DEVELOPMENT 313
15.11 GLENMARK PHARMACEUTICALS LTD. 314
15.11.1 COMPANY SNAPSHOT 314
15.11.2 REVENUE ANALYSIS 315
15.11.3 PRODUCT PORTFOLIO 315
15.11.4 RECENT DEVELOPMENT 316
15.12 JOHNSON & JOHNSON SERVICES, INC. 317
15.12.1 COMPANY SNAPSHOT 317
15.12.2 REVENUE ANALYSIS 317
15.12.3 PRODUCT PORTFOLIO 318
15.12.4 RECENT DEVELOPMENT 318
15.13 LUPIN 319
15.13.1 COMPANY SNAPSHOT 319
15.13.2 REVENUE ANALYSIS 320
15.13.3 PRODUCT PORTFOLIO 320
15.13.4 RECENT DEVELOPMENT 321
15.14 MEDTRONIC 322
15.14.1 COMPANY SNAPSHOT 322
15.14.2 REVENUE ANALYSIS 322
15.14.3 PRODUCT PORTFOLIO 323
15.14.4 RECENT DEVELOPMENT 324
15.15 PENUMBRA, INC. 325
15.15.1 COMPANY SNAPSHOT 325
15.15.2 REVENUE ANALYSIS 326
15.15.3 PRODUCT PORTFOLIO 326
15.15.4 RECENT DEVELOPMENT 327
15.16 PFIZER INC. 328
15.16.1 COMPANY SNAPSHOT 328
15.16.2 REVENUE ANALYSIS 329
15.16.3 PRODUCT PORTFOLIO 330
15.16.4 RECENT DEVELOPMENT 330
15.17 SANDOZ AG 331
15.17.1 COMPANY SNAPSHOT 331
15.17.2 REVENUE ANALYSIS 331
15.17.3 PRODUCT PORTFOLIO 332
15.17.4 RECENT DEVELOPMENT 333
15.18 TEVA PHARMACEUTICALS USA, INC. 334
15.18.1 COMPANY SNAPSHOT 334
15.18.2 REVENUE ANALYSIS 334
15.18.3 PRODUCT PORTFOLIO 335
15.18.4 RECENT DEVELOPMENT 336
15.19 VIATRIS INC. 337
15.19.1 COMPANY SNAPSHOT 337
15.19.2 REVENUE ANALYSIS 337
15.19.3 PRODUCT PORTFOLIO 338
15.19.4 RECENT DEVELOPMENT 339
16 QUESTIONNAIRE 340
17 RELATED REPORTS 343
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security